Therapeutic resistance of pancreatic cancer: Roadmap to its reversal

被引：87
作者：
Yu, Sen [1 ]
Zhang, Chunyu [1 ]
Xie, Ke-Ping [1 ]
机构：
[1] South China Univ Technol, Sch Med, Dept Gastroenterol & Hepatol, Guangzhou Peoples Hosp Affiliated 1, Guangzhou, Guangdong, Peoples R China
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2021年 / 1875卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Pancreatic cancer; Chemotherapy; Radiotherapy; Immunotherapy; Therapeutic resistance; GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; ANABOLIC GLUCOSE-METABOLISM; CARBOHYDRATE ANTIGEN 19-9; PHASE-III TRIAL; GEMCITABINE RESISTANCE; DUCTAL ADENOCARCINOMA; DNA-DAMAGE; UP-REGULATION; TUMOR-CELLS;
D O I：
10.1016/j.bbcan.2020.188461
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Pancreatic cancer is a lethal disease with limited opportunity for resectable surgery as the first choice for cure due to its late diagnosis and early metastasis. The desmoplastic stroma and cellular genetic or epigenetic alterations of pancreatic cancer impose physical and biological barriers to effective therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Here, we review the current therapeutic options for pancreatic cancer, and underlying mechanisms and potential reversal of therapeutic resistance, a hallmark of this deadly disease.
引用
收藏
页数：16
相关论文
共 244 条
  • [11] Functionalized nanoparticles enable tracking the rapid entry and release of doxorubicin in human pancreatic cancer cells
    Arachchige, Maheshika P.
    Laha, Suvra S.
    Naik, Akshata R.
    Lewis, Kenneth T.
    Naik, Ratna
    Jena, Bhanu P.
    [J]. MICRON, 2017, 92 : 25 - 31
  • [12] Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
    Arumugam, Thiruvengadam
    Ramachandran, Vijaya
    Fournier, Keith F.
    Wang, Huamin
    Marquis, Lauren
    Abbruzzese, James L.
    Gallick, Gary E.
    Logsdon, Craig D.
    McConkey, David J.
    Choi, Woonyoung
    [J]. CANCER RESEARCH, 2009, 69 (14) : 5820 - 5828
  • [13] Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Kronenberger, David
    Stefaniak, Alexis
    Hassan, Md Sazzad
    von Holzen, Urs
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    [J]. CANCER LETTERS, 2019, 459 : 41 - 49
  • [14] Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
    Bachem, MG
    Schünemann, M
    Ramadani, M
    Siech, M
    Beger, H
    Buck, A
    Zhou, SX
    Schmid-Kotsas, A
    Adler, G
    [J]. GASTROENTEROLOGY, 2005, 128 (04) : 907 - 921
  • [15] Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
    Bailey, Jennifer M.
    Swanson, Benjamin J.
    Hamada, Tomofumi
    Eggers, John P.
    Singh, Pankaj K.
    Caffery, Thomas
    Ouellette, Michel M.
    Hollingsworth, Michael A.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (19) : 5995 - 6004
  • [16] Genomic analyses identify molecular subtypes of pancreatic cancer
    Bailey, Peter
    Chang, David K.
    Nones, Katia
    Johns, Amber L.
    Patch, Ann-Marie
    Gingras, Marie-Claude
    Miller, David K.
    Christ, Angelika N.
    Bruxner, Tim J. C.
    Quinn, Michael C.
    Nourse, Craig
    Murtaugh, L. Charles
    Harliwong, Ivon
    Idrisoglu, Senel
    Manning, Suzanne
    Nourbakhsh, Ehsan
    Wani, Shivangi
    Fink, Lynn
    Holmes, Oliver
    Chin, Vencssa
    Anderson, Matthew J.
    Kazakoff, Stephen
    Leonard, Conrad
    Newell, Felicity
    Waddell, Nick
    Wood, Scott
    Xu, Qinying
    Wilson, Peter J.
    Cloonan, Nicole
    Kassahn, Karin S.
    Taylor, Darrin
    Quek, Kelly
    Robertson, Alan
    Pantano, Lorena
    Mincarelli, Laura
    Sanchez, Luis N.
    Evers, Lisa
    Wu, Jianmin
    Pinese, Mark
    Cowley, Mark J.
    Jones, Marc D.
    Colvin, Emily K.
    Nagrial, Adnan M.
    Humphrey, Emily S.
    Chantrill, Lorraine A.
    Mawson, Amanda
    Humphris, Jeremy
    Chou, Angela
    Pajic, Marina
    Scarlett, Christopher J.
    [J]. NATURE, 2016, 531 (7592) : 47 - +
  • [17] The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal
    Ballehaninna, Umashankar K.
    Chamberlain, Ronald S.
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2012, 3 (02) : 105 - 119
  • [18] A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy
    Bao, Xiuli
    Wang, Wei
    Wang, Cheng
    Wang, Yu
    Zhou, Jianping
    Ding, Yang
    Wang, Xiaoyi
    Jin, Yuting
    [J]. BIOMATERIALS, 2014, 35 (29) : 8450 - 8466
  • [19] A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with 19F NMR spectroscopy
    Bapiro, Tashinga E.
    Richards, Frances M.
    Goldgraben, Mae A.
    Olive, Kenneth P.
    Madhu, Basetti
    Frese, Kristopher K.
    Cook, Natalie
    Jacobetz, Michael A.
    Smith, Donna-Michelle
    Tuveson, David A.
    Griffiths, John R.
    Jodrell, Duncan I.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1243 - 1253
  • [20] Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy
    Bauer, Todd M.
    El-Rayes, Bassel F.
    Li, Xiaobai
    Hammad, Nazik
    Philip, Philip A.
    Shields, Anthony F.
    Zalupski, Mark M.
    Bekaii-Saab, Tanios
    [J]. CANCER, 2013, 119 (02) : 285 - 292
12345678910